Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,889 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The Tumor Microbiome as a Predictor of Outcomes in Patients with Metastatic Melanoma Treated with Immune Checkpoint Inhibitors.
Dravillas CE, Coleman SS 4th, Hoyd R, Caryotakis G, Denko L, Chan CHF, Churchman ML, Denko N, Dodd RD, Eljilany I, Hardikar S, Husain M, Ikeguchi AP, Jin N, Ma Q, McCarter MD, Osman AEG, Robinson LA, Singer EA, Tinoco G, Ulrich CM, Zakharia Y, Spakowicz D, Tarhini AA, Tan AC; exORIEN Consortium. Dravillas CE, et al. Among authors: husain m. Cancer Res Commun. 2024 Aug 1;4(8):1978-1990. doi: 10.1158/2767-9764.CRC-23-0170. Cancer Res Commun. 2024. PMID: 39015091 Free PMC article.
Change in neutrophil to lymphocyte ratio during immunotherapy treatment is a non-linear predictor of patient outcomes in advanced cancers.
Li M, Spakowicz D, Burkart J, Patel S, Husain M, He K, Bertino EM, Shields PG, Carbone DP, Verschraegen CF, Presley CJ, Otterson GA, Kendra K, Owen DH. Li M, et al. Among authors: husain m. J Cancer Res Clin Oncol. 2019 Oct;145(10):2541-2546. doi: 10.1007/s00432-019-02982-4. Epub 2019 Jul 31. J Cancer Res Clin Oncol. 2019. PMID: 31367835 Free PMC article.
Inferring the role of the microbiome on survival in patients treated with immune checkpoint inhibitors: causal modeling, timing, and classes of concomitant medications.
Spakowicz D, Hoyd R, Muniak M, Husain M, Bassett JS, Wang L, Tinoco G, Patel SH, Burkart J, Miah A, Li M, Johns A, Grogan M, Carbone DP, Verschraegen CF, Kendra KL, Otterson GA, Li L, Presley CJ, Owen DH. Spakowicz D, et al. Among authors: husain m. BMC Cancer. 2020 May 6;20(1):383. doi: 10.1186/s12885-020-06882-6. BMC Cancer. 2020. PMID: 32375706 Free PMC article.
Brief report: inhaled corticosteroid use and the risk of checkpoint inhibitor pneumonitis in patients with advanced cancer.
Li M, Spakowicz D, Zhao S, Patel SH, Johns A, Grogan M, Miah A, Husain M, He K, Bertino EM, Shields PG, Wei L, Carbone DP, Otterson GA, Presley CJ, Owen DH. Li M, et al. Among authors: husain m. Cancer Immunol Immunother. 2020 Nov;69(11):2403-2408. doi: 10.1007/s00262-020-02674-w. Epub 2020 Jul 29. Cancer Immunol Immunother. 2020. PMID: 32728772 Free PMC article.
Checkpoint inhibitor immunotherapy toxicity and overall survival among older adults with advanced cancer.
Johns AC, Wei L, Grogan M, Hoyd R, Bridges JFP, Patel SH, Li M, Husain M, Kendra KL, Otterson GA, Burkart JT, Rosko AE, Andersen BL, Carbone DP, Owen DH, Spakowicz DJ, Presley CJ. Johns AC, et al. Among authors: husain m. J Geriatr Oncol. 2021 Jun;12(5):813-819. doi: 10.1016/j.jgo.2021.02.002. Epub 2021 Feb 21. J Geriatr Oncol. 2021. PMID: 33627226 Free PMC article.
Immune checkpoint inhibitor-induced hepatitis injury: risk factors, outcomes, and impact on survival.
Miah A, Tinoco G, Zhao S, Wei L, Johns A, Patel S, Li M, Grogan M, Lopez G, Husain M, Hoyd R, Mumtaz K, Meara A, Bertino EM, Kendra K, Spakowicz D, Otterson GA, Presley CJ, Owen DH. Miah A, et al. Among authors: husain m. J Cancer Res Clin Oncol. 2023 May;149(5):2235-2242. doi: 10.1007/s00432-022-04340-3. Epub 2022 Sep 7. J Cancer Res Clin Oncol. 2023. PMID: 36070148 Free PMC article. Review.
Association of medical comorbidities and cardiovascular disease with toxicity and survival among patients receiving checkpoint inhibitor immunotherapy.
Johns AC, Yang M, Wei L, Grogan M, Patel SH, Li M, Husain M, Kendra KL, Otterson GA, Burkart JT, Spakowicz D, Hoyd R, Owen DH, Presley CJ. Johns AC, et al. Among authors: husain m. Cancer Immunol Immunother. 2023 Jul;72(7):2005-2013. doi: 10.1007/s00262-023-03371-0. Epub 2023 Feb 4. Cancer Immunol Immunother. 2023. PMID: 36738310 Free PMC article.
Emerging Trends in Immunotherapy for Adult Sarcomas.
Husain M, Chen L, Liebner D, Beane J, Rubinstein M, Pollock R, Verschraegen C, Tinoco G. Husain M, et al. Oncologist. 2023 May 8;28(5):e233-e241. doi: 10.1093/oncolo/oyad052. Oncologist. 2023. PMID: 36905579 Free PMC article.
Clinical markers of immunotherapy outcomes in advanced sarcoma.
Husain M, Quiroga D, Kim HG, Lenobel S, Xu M, Iwenofu H, Chen JL, Verschraegen C, Liebner D, Tinoco G. Husain M, et al. BMC Cancer. 2023 Apr 7;23(1):326. doi: 10.1186/s12885-023-10758-w. BMC Cancer. 2023. PMID: 37029351 Free PMC article.
1,889 results